TITLE

Draxis Debuts Alertec For Treatment Of Narcolepsy

PUB. DATE
July 1999
SOURCE
Worldwide Biotech;Jul99, Vol. 11 Issue 7, p3
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that DRAXIS Health Inc. launched the drug product, Alertec, in the Canadian marketplace. Therapeutic use of Alertec; Reactions from Dr. Roger Broughton and Dr. Ed Gibson; Information on DRAXIS.
ACCESSION #
2107046

 

Related Articles

  • Product Summaries.  // Worldwide Biotech;Aug99, Vol. 11 Issue 8, p3 

    Presents information on the neurology products being marketed by Draxis Health Inc. in Canada. Mechanism of action of Zanaflex; Diastat; Mysoline.

  • DRAXIS Acquires Canadian Rights to 8 Elan Neurology Products.  // Worldwide Biotech;Aug99, Vol. 11 Issue 8, p2 

    Reports that Draxis Health Inc. has in-licensed from Elan Corp. PLC the exclusive Canadian rights to eight neurology products. Conditions under the agreement; Task of Draxis Pharmaceutica; Comments from officials of both companies.

  • GE Healthcare in pact to distribute Draximage's Sestamibi product.  // Medical Device Daily;12/26/2007, Vol. 11 Issue 233, p5 

    The article reports on an agreement entered into by GE Healthcare, a developer of diagnostic imaging technologies, with Draxis Health, to become the exclusive distributor of Draximage's Sestamibi imaging product upon its approval by the U.S. Food and Drug Administration and the expiration of the...

  • DRAXIS REPORTS NET INCOME OF $806.000 FOR FIRST QTR '03.  // Biotech Financial Reports;Jul2003, p3 

    Mississauga, Ontario-based Draxis Health Inc. has reported financial results for the first quarter of 2003 ended March 31, 2003. Net income from continuing operations was $806,000 versus $978,000 for the same quarter in 2002. Net income from discontinued operations was $4.2 million. Earnings...

  • Nutritional firm partially bought by drug company.  // Indianapolis Business Journal;6/19/95, Vol. 16 Issue 12, p45A 

    Reports on Draxis Health Inc. of Canada's partial purchase of Indianapolis, Ind.-based Innovative Health Systems. Terms of the purchase agreement.

  • DRAXIS Builds New Facility.  // Pharmaceutical Technology;Jan2008, Vol. 32 Issue 1, p110 

    The article reports that Montreal, Quebec-based specialty pharmaceutical company DRAXIS Health began the construction of its new packaging and warehousing facility in St-Anne-de-Bellevue. The facility, which is expected to be completed by mid of 2008, was intended to help the company produce...

  • DRAXIS DIVESTS TIAMOL/KERASAL PRODUCT LINES TO TARO.  // Biotech Financial Reports;Aug2000, p3 

    Focuses on Ontario-based DRAXIS Health Inc.'s signing of an agreement to dispose of its Tiamol and Kerasal dermatological product lines to Taro Pharmaceuticals Industries Ltd. Value of the transaction; Completion of firm's divestiture of its dermatology marketing and selling operations.

  • DRAXIS PROVIDES UPDATE FOR FOURTH QUARTER.  // Biotech Financial Reports;Jan2006, p1 

    The article focuses on Draxis Health Inc.'s updated expectations for the fourth quarter of 2005. Draxis Health expects that total consolidated revenues and basic earnings per share for the fourth quarter may not be materially better than the corresponding results in the third quarter of 2005....

  • Draxis expands its role with J&J's consumer goods unit.  // Medical Device Daily;9/24/2007, Vol. 11 Issue 182, p1 

    The article reports that Draxis Specialty Pharmaceuticals, the contract manufacturing division of Draxis Health, has expanded its existing contract manufacturing relationship with Johnson & Johnson Consumer Companies by entering into an agreement to provide commercial manufacturing services for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics